The NIH’s funding opportunity (RFA-AI-24-068) supports research on new therapeutic strategies for genital herpes, emphasizing approaches to reduce viral shedding, lesion formation, and transmission. This grant, structured as a two-phase R21/R33 mechanism, invites projects exploring various treatment avenues, including novel antivirals, monoclonal antibodies, therapeutic vaccines, and gene editing technologies. While clinical trials are not permitted, applicants must achieve specific milestones in the initial phase (R21) to progress to the second phase (R33).

Eligible applicants include higher education institutions, nonprofits, government agencies, tribal entities, for-profit organizations (excluding small businesses), and minority-serving institutions such as HBCUs and Hispanic-serving Institutions. Foreign entities are permitted as components of U.S.-based applications.

There is no cost-sharing requirement, and while specific funding limits are not disclosed, projects will proceed to phase two only if initial goals are met. Applications are due by January 31, 2025, and further details are available through the NIH link provided. Interested applicants are encouraged to reach out to NIH for guidance.